Edwards Lifesciences Co. (NYSE:EW) Position Decreased by DF Dent & Co. Inc.

DF Dent & Co. Inc. reduced its holdings in Edwards Lifesciences Co. (NYSE:EW) by 16.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 543,873 shares of the medical research company’s stock after selling 109,330 shares during the quarter. DF Dent & Co. Inc. owned 0.09% of Edwards Lifesciences worth $35,890,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Stableford Capital II LLC lifted its position in shares of Edwards Lifesciences by 2.7% during the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock worth $533,000 after buying an additional 159 shares during the period. Purus Wealth Management LLC raised its stake in Edwards Lifesciences by 5.2% during the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after acquiring an additional 160 shares in the last quarter. Busey Bank lifted its holdings in shares of Edwards Lifesciences by 1.9% during the second quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 165 shares during the period. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Edwards Lifesciences by 7.4% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 2,415 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 166 shares in the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent analyst reports. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Wells Fargo & Company lowered their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average price target of $78.35.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Down 1.2 %

Shares of NYSE:EW opened at $71.53 on Friday. The company has a 50 day moving average price of $68.55 and a two-hundred day moving average price of $74.76. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $42.19 billion, a PE ratio of 10.32, a PEG ratio of 4.17 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the business posted $0.59 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. Analysts forecast that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.